関西医科大学附属病院は、大阪府枚方市にある大学病院。 地域がん診療連携拠点病院や大阪府災害拠点病院、大阪府の災害派遣医療チームの大阪DMATなどの指定を受けている。 週刊ダイヤモンドの特集「頼れる病院ランキング」の記事で、附属病院が3年連続で大阪府1位に、附属滝井病院が大阪府10位に選ばれた。

During the past decade, Kansai Medical University Hospital conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 11 clinical trials were completed, i.e. on average, 27.5% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 9 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansai Medical University Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Incyte Corporation" with 4 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansai Medical University Hospital" #1 collaborator was "Alpha-A, Inc." with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Australasian Lung Cancer Trials Group" with 1 trials as a collaborator, "Brightech International" with 1 trials as a collaborator and "Central and Eastern European Oncology Group" with 1 trials as a collaborator. Other collaborators include 25 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "Kansai Medical University Hospital" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Non-Small Cell Lung Cancer" (3 trials), "Psoriasis" (3 trials), "Breast Neoplasms" (2 trials) and "Coronary Artery Disease" (2 trials). Many other conditions were trialed in "Kansai Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Kansai Medical University Hospital" are "Drug" (43 trials), "Biological" (3 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Carboplatin" (6 trials), "Pemetrexed" (5 trials), "Amivantamab" (3 trials) and "Lazertinib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Kansai Medical University Hospital" are 45 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Kansai Medical University Hospital". undefined are not yet recruiting, 17 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Kansai Medical University Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kansai Medical University Hospital, 5 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".